Febuxostat for the Management of Hyperuricaemia in Patients with Gout: A NICE Single Technology Appraisal

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.29, Iss.2, 2011-02, pp. : 133-140

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout

By Schumacher Jr H Ralph

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 7, 2005-07 ,pp. : 893-903

Informa Healthcare

Access to resources Recommend Favorite

Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery: A NICE Single Technology Appraisal

By Holmes Michael Carroll Christopher Papaioannou Diana

PharmacoEconomics, Vol. 30, Iss. 2, 2012-02 ,pp. : 137-146

Adis International

Access to resources Recommend Favorite

Dronedarone for the Treatment of Atrial Fibrillation: A NICE Single Technology Appraisal

By McKenna Claire

PharmacoEconomics, Vol. 30, Iss. 1, 2012-01 ,pp. : 35-46

Adis International

Access to resources Recommend Favorite

Bevacizumab for Metastatic Colorectal Cancer: A NICE Single Technology Appraisal

By Whyte Sophie Pandor Abdullah Stevenson Matt

PharmacoEconomics, Vol. 30, Iss. 12, 2012-12 ,pp. : 1119-1132

Adis International

Access to resources Recommend Favorite

Alitretinoin for Severe Chronic Hand Eczema: A NICE Single Technology Appraisal

By Rodgers Mark

PharmacoEconomics, Vol. 28, Iss. 5, 2010-05 ,pp. : 351-362

Adis International

Access to resources Recommend Favorite